share_log

Affimed to Review Clinical Data From Lung Cancer Trial on December 17

Affimed to Review Clinical Data From Lung Cancer Trial on December 17

Affimed將在12月17日審查肺癌臨床試驗的數據
Benzinga ·  2024/12/09 19:41

Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE with atezolizumab in non-small cell lung cancer.

Affimed N.V. (納斯達克:AFMD) ("Affimed"或"公司"), 一家致力於幫助患者恢復對抗癌症的固有能力的臨床階段免疫腫瘤學公司,今天宣佈將於12月17日星期二上午8:30(東部標準時間)/ 下午2:30(中部歐洲時間)召開電話會議,以回顧AFM24-102臨床數據,這是其AFM24電芯結合atezolizumab用於非小細胞肺癌的組合試驗。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論